South Korea Adalimumab Market to 2032
Overview
The South Korea Adalimumab Market is expected to reach a 235.31 USD Billion by 2032 and is projected to grow at a CAGR of 11.03% from 2025 to 2032.
Revenue, 2024 (USD Billion)
136.11
Forecast, 2032 (USD Billion)
235.31
CAGR, 2024 - 2032
11.03%
Report Coverage
South Korea
South Korea Adalimumab Market 2018-2032 USD Billion
South Korea Adalimumab Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 136.11 USD Billion
- Projected Market Size (2032): 235.31 USD Billion
- CAGR (2025-2032): 11.03%
Key Findings of South Korea Adalimumab Market
- The South Korea Adalimumab Market was valued at 136.11 USD Billion in 2024.
- The South Korea Adalimumab Market is likely to grow at a CAGR of 11.03% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Parenteral (SC) in Route of Administration Segment accounted for the largest share of the market with a revenue of 136.11 USD Billion
- The fastest growing segment Biosimilars in Type Segment grew Fastest with a CAGR of 28.24% during the forecast period from 2024 to 2032.
South Korea Adalimumab Market Scope
South Korea Adalimumab Market Segmentation & Scope
Indication
- Others
- Non-Infectious Intermediate
- Hidradenitis Suppurativa
- Juvenile Idiopathic Arthritis
- Psoriatic Arthritis
- Ulcerative Colitis
- Crohn's Disease
- Chronic Plaque Psoriasis
- Ankylosing Spondylitis
- Rheumatoid Arthritis
Type
- Biosimilars
- Biologics
Population Type
- Children
- Adults
End User
- Others
- Home Healthcare
- Specialty Clinics
- Hospitals
Distribution Channel
- Others
- Direct Tenders
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
Route of Administration
- Oral
- Parenteral (SC)
Dosage Strength
- Others
- 10mg/0.1ml
- 20mg/0.4ml
- 80mg/0.8ml
- 40mg/0.4ml
Drug Type
- Generics
- Branded
South Korea Adalimumab Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2020 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 136.11 USD Billion |
| Market Value in 2032 | 235.31 USD Billion |
| CAGR (2025-2032) | 11.03% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Indication,Type,Population Type,End User,Distribution Channel,Route of Administration,Dosage Strength,Drug Type |
Regional Insights:
-
Leading Market (2024-2032): South Korea, leading in terms of revenue 136.11 USD Billion in 2024
- Key Country: South Korea, leading in terms of revenue with value of 136.11 USD Billion in 2024.
Segments and Scope
-
South Korea Adalimumab Market to 2032, By Indication
- Rheumatoid Arthritis is the largest segment in South Korea Adalimumab Market to 2032 with a revenue of 55.70 USD Billion in the year 2024.
- Ankylosing Spondylitis is the Fastest growing segment in South Korea Adalimumab Market to 2032 with a Growth rate of 11.38 % in forecast period 2025-2032.
-
South Korea Adalimumab Market to 2032, By Type
- Biosimilars is the largest segment in South Korea Adalimumab Market to 2032 with a revenue of 77.92 USD Billion in the year 2024.
- Biosimilars is the Fastest growing segment in South Korea Adalimumab Market to 2032 with a Growth rate of 28.24 % in forecast period 2025-2032.
-
South Korea Adalimumab Market to 2032, By Population Type
- Adults is the largest segment in South Korea Adalimumab Market to 2032 with a revenue of 100.19 USD Billion in the year 2024.
- Children is the Fastest growing segment in South Korea Adalimumab Market to 2032 with a Growth rate of 10.68 % in forecast period 2025-2032.
-
South Korea Adalimumab Market to 2032, By End User
- Hospitals is the largest segment in South Korea Adalimumab Market to 2032 with a revenue of 75.34 USD Billion in the year 2024.
- Specialty Clinics is the Fastest growing segment in South Korea Adalimumab Market to 2032 with a Growth rate of 10.85 % in forecast period 2025-2032.
-
South Korea Adalimumab Market to 2032, By Distribution Channel
- Hospital Pharmacies is the largest segment in South Korea Adalimumab Market to 2032 with a revenue of 75.89 USD Billion in the year 2024.
- Retail Pharmacies is the Fastest growing segment in South Korea Adalimumab Market to 2032 with a Growth rate of 10.79 % in forecast period 2025-2032.
-
South Korea Adalimumab Market to 2032, By Route of Administration
- Parenteral (SC) is the largest segment in South Korea Adalimumab Market to 2032 with a revenue of 136.11 USD Billion in the year 2024.
- Parenteral (SC) is the Fastest growing segment in South Korea Adalimumab Market to 2032 with a Growth rate of 11.03 % in forecast period 2025-2032.
-
South Korea Adalimumab Market to 2032, By Dosage Strength
- 40mg/0.4ml is the largest segment in South Korea Adalimumab Market to 2032 with a revenue of 60.09 USD Billion in the year 2024.
- 40mg/0.4ml is the Fastest growing segment in South Korea Adalimumab Market to 2032 with a Growth rate of 11.56 % in forecast period 2025-2032.
-
South Korea Adalimumab Market to 2032, By Drug Type
- Generics is the largest segment in South Korea Adalimumab Market to 2032 with a revenue of 77.92 USD Billion in the year 2024.
- Generics is the Fastest growing segment in South Korea Adalimumab Market to 2032 with a Growth rate of 28.24 % in forecast period 2025-2032.
South Korea Adalimumab Market Company Share Analysis
South Korea Adalimumab Market Geographical Sales Distribution, 2018-2032 USD Billion
South Korea Adalimumab Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The South Korea Adalimumab Market is segmented based on Segmentation Indication,Type,Population Type,End User,Distribution Channel,Route of Administration,Dosage Strength,Drug Type.
South Korea Adalimumab Market was valued at USD 136.11(Revenue in USD Billion) in 2020.
South Korea Adalimumab Market is projected to grow at a CAGR of 11.03% during the forecast period of 2024 to 2032.
The Parenteral (SC) segment is expected to dominate the South Korea Adalimumab Market, holding a largest market share of 136.11 USD Billion in 2024
South Korea Adalimumab Market Scope
South Korea Adalimumab Market Segmentation & Scope
Indication
- Others
- Non-Infectious Intermediate
- Hidradenitis Suppurativa
- Juvenile Idiopathic Arthritis
- Psoriatic Arthritis
- Ulcerative Colitis
- Crohn's Disease
- Chronic Plaque Psoriasis
- Ankylosing Spondylitis
- Rheumatoid Arthritis
Type
- Biosimilars
- Biologics
Population Type
- Children
- Adults
End User
- Others
- Home Healthcare
- Specialty Clinics
- Hospitals
Distribution Channel
- Others
- Direct Tenders
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
Route of Administration
- Oral
- Parenteral (SC)
Dosage Strength
- Others
- 10mg/0.1ml
- 20mg/0.4ml
- 80mg/0.8ml
- 40mg/0.4ml
Drug Type
- Generics
- Branded
Frequently Asked Questions
The South Korea Adalimumab Market is segmented based on Segmentation Indication,Type,Population Type,End User,Distribution Channel,Route of Administration,Dosage Strength,Drug Type.
South Korea Adalimumab Market was valued at USD 136.11(Revenue in USD Billion) in 2020.
South Korea Adalimumab Market is projected to grow at a CAGR of 11.03% during the forecast period of 2024 to 2032.
The estimated market value of the South Korea Adalimumab Market for final year is USD 235.31 (USD Billion).
South Korea Adalimumab Market Company Profiling
Frequently Asked Questions
The South Korea Adalimumab Market is segmented based on Segmentation Indication,Type,Population Type,End User,Distribution Channel,Route of Administration,Dosage Strength,Drug Type.
South Korea Adalimumab Market was valued at USD 136.11(Revenue in USD Billion) in 2020.
South Korea Adalimumab Market is projected to grow at a CAGR of 11.03% during the forecast period of 2024 to 2032.
The estimated market value of the South Korea Adalimumab Market for final year is USD 235.31 (USD Billion).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.